RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Eargo, a Silicon Valley direct-to-consumer hearing aid company, closed the first tranche of a $45 million Series C round, led by Hong Kong’s Nan Fung Life Sciences Fund. The round included investors New Enterprise Associates, Charles and Helen Schwab, and Maveron. Eargo makes a small, nearly invisible hearing aid that it says is comfortable and rechargeable. The device, which costs just under $2,000 per pair, is a Class I, FDA-regulated product.
Source: ChinaBio Today
